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Abstract
Background: Previous estimates for the prevalence of musculoskeletal conditions (MSK) and chronic pain in
Australia have been based on self-report. We aimed to determine the prevalence and distribution of arthritis,
chronic back pain, gout, osteoporosis, spondyloarthropathies and rheumatoid arthritis and current consultations
for chronic pain among adults attending Australian general practice, and describe their distribution according to
sociodemographic characteristics and presence of co-morbidities.
Methods: We investigated 1,501,267 active adult patients (57.6% females; 22.5% ≥65y) evaluated between 2013 and
2016 and included in the MedicineInsight database (a National Prescribing Service MedicineWise program), a large
general practice data program that extracts longitudinal de-identified electronic medical record data from ‘active’ patients
in over 550 practices. Three main groups of outcomes were investigated: 1) “prevalence” of arthritis, chronic back pain,
gout, osteoporosis, spondyloarthropathies, and/or rheumatoid arthritis between 2000 and 2016; 2) “current” diagnosis/
encounter for the same conditions occurring between 2013 and 2016, and; 3) “current” consultations for chronic pain of
any type occurring between 2013 and 2016.
Results: The combined “prevalence” of the investigated MSK (diagnosis between 2000 and 2016) among adults
attending Australian general practice was 16.8% (95%CI 15.9;17.7) with 21.3% (95%CI 20.2;22.4) of the sample
consulting for chronic pain between 2013 and 2016. The investigated MSK with the highest “prevalence” were
arthritis (9.5%) and chronic back pain (6.7%). Patients with some of these MSK attended general practices more
frequently than those without these conditions (median 2.0 and 1.0 contacts/year, respectively). The “prevalence”
of the investigated MSK and “current” consultations for chronic pain increased with age, especially in women, but
chronic pain remained stable at 22% for males aged > 40 years. The investigated MSK and chronic pain were
more frequent among those in lower socioeconomic groups, veterans, Aboriginal and Torrent Strait Islanders,
current and ex-smokers, and patients with chronic obstructive pulmonary disease or heart failure.
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Conclusions: The investigated MSK are more frequent among lower socioeconomic groups and the elderly. Based on
information collected from adults attending Australian general practices, MedicineInsight provided similar estimates to
those obtained from population-based studies, with the advantage of being based on medical diagnosis and including
a national sample.
Keywords: Pain, chronic, Back pain, Musculoskeletal, Arthritis, Epidemiology, Population health
Background
Musculoskeletal conditions (MSK) and chronic pain rep-
resent an increasing public health problem worldwide
[1–5]. According to the Australian Institute of Health
and Welfare (AIHW) and the National Health Survey
(NHS), in 2011 they affected 28% of Australian adults
(6.1 million) [6]. Due to their chronicity and impact on
health status and quality of life, they represent the fourth
most expensive group of diseases in Australia, account-
ing for 9% of total health-care expenditure related to
hospitalisations, out-of-hospital health care, and pre-
scribed medications (approximately AUD$5.7 billion of
the AUD$65 billion spent for all diseases) [7]. In terms
of health service use, in 2010 they were among the ten
most frequent problems managed by general practi-
tioners (GPs) (2.7 per 100 encounters for osteoarthritis
and 2.6 for back pain), only after metabolic conditions
and depression [8].
A few surveys have used self-reported data to investi-
gate the prevalence of these conditions among Austra-
lian adults [6, 9, 10], while the Bettering the Evaluation
and Care of Health (BEACH) program reported encoun-
ter rates and medication use for MSK and chronic pain
in adults attending a random sample of Australian gen-
eral practices [11, 12]. Estimates for MSK and chronic
pain vary across studies and information bias has been
highlighted as one of the reasons for these differences
[13–15]. Self-report for chronic pain and some MSK is
less accurate than for sociodemographic characteristics,
lifestyle, or other chronic conditions, thus affecting the
ability of population-based surveys to provide accurate
estimates for the total burden of MSK [14, 15]. On the
other hand, studies on this topic using nationally repre-
sentative samples and based on medical diagnosis are
scarce in the scientific literature [3–5, 13].
The Australian Government have recognised MSK and
chronic pain as a major public health priority, and empha-
sised the importance of national real-time data for moni-
toring their prevalence, management, and adverse effects
of medications [16]. More generally, increasing the scope
and number of quality improvement activties has been
recognised as being important for the Australian health
care system and so the National Prescribing Service (NPS)
MedicineWise was funded in 2011 to periodically collect
longitudinal clinical and prescribing data from Australian
general practices through MedicineInsight [17]. Utilising
this large ongoing dataset, we aimed to investigate the
prevalence of some MSK conditions (arthritis, chronic
back pain, gout, osteoporosis, spondyloarthropathies, and
rheumatoid arthritis) and consultations for chronic pain
among adults attending Australian general practices, de-
scribe their distribution according to patients’ sociodemo-
graphic characteristics and examine associations with
other chronic non-communicable diseases (NCDs).
Methods
NPS MedicineWise was established in 1998 as an inde-
pendent, evidence-based, not-for-profit organisation. It
aims to promote the quality use of medicines. In 2011,
NPS MedicineWise established MedicineInsight to drive
quality improvement activities in general practice and im-
prove primary health care and post marketing surveillance
of medicine use in Australia [17]. MedicineInsight uses a
data extraction tool (GRHANITE™) developed by the
University of Melbourne and NPS MedicineWise, which
weekly collects de-identified data from patients electronic
medical records and securely transfers the information to
NPS MedicineWise [17, 18]. Based on a unique identifying
number attributed to everyone, patients within practices
are tracked over time, allowing the development of an on-
going longitudinal database.
Patients’ information collected by MedicineInsight in-
clude: demographics (gender, ethnicity, indigenous status,
year of birth, postcode, suburb), diagnoses, reasons for
consultations, medicines prescribed and reasons for pre-
scription, known allergies or drug reactions, pathology test
orders and results, imaging test orders, instances of refer-
rals to other healthcare professionals (excluding referral
documents), instances of patient assessment and manage-
ment activities, clinical measurements (temperature, blood
pressure, weight, height, waist circumference), and smok-
ing status. For privacy reasons, a complete patient’s listed
past medical history (PMH considering the whole patient
lifespan) is not collected by MedicineInsight [17]. How-
ever, by aggregating the information collected over several
years at each general practice (46% of individuals with
available electronic medical records prior to the launch of
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MedicineInsight in 2011), the data extraction tool gener-
ates a “partial” clinical history for all active patients based
on previous diagnoses, medications, laboratory results,
and hospital admissions [17, 19–21].
Depending on the clinical information system available
at each general practice, GPs used medical coding vocabu-
laries (i.e. ‘DOCLE’, ‘PYEFINCH’ or ‘ICPC’) to register
medical diagnosis, reasons for encounter, and reason for
prescription into their systems. Although GPs are required
to complete all these fields every time they see a patient,
the use of the codes is not mandatory and clinicians can
enter medical terms as free text [17].
By the end on 2016, MedicineInsight had recruited 557
Australian general practices. Although a non-random
sampling process is used, the sample includes practices
from all states/territories (New South Wales (NSW) =
29.5%; Victoria (VIC) = 22.7%; Queensland (QLD) =
20.1%; Western Australia (WA) = 12.2%; Tasmania (TAS)
= 7.9%; South Australia (SA) = 3.6%; Australia Capital Ter-
ritory (ACT) = 2.0%; North Territory (NT) = 2.0%), regions
(major cities = 59.0%; inner regional = 24.5%; outer re-
gional = 12.6%; remote/very remote =3.8%), and size (1
GP = 6.9%; 2 GPs = 11.6%; 3–5 GPs = 38.0%; 6–8 GPs =
24.0%; > 8 Gps = 19.5%) [17]. Following recommendations
for improving data quality [20–23], only practices estab-
lished for ≥2 years before the end of the analysis period
(no interruptions > 2 months in practice), with recorded
data (history item, reason for encounter, or reason for pre-
scription) in ≥10% of encounters, and an average of ≥30
prescriptions/week were included in the analyses. There-
fore, we used data collected by MedicineInsight from all
active patients (three or more visits to the practice in the
past 2 years) attending 4668 GPs (14.0% of the 33,275 GPs
registered in Australia in 2014–15) in 329 general prac-
tices across Australia (4.7% of all 7035 practices in 2011)
[24, 25]. All patients aged 18 and above, with information
registered in a MedicineInsight practice between 10/2013
and 06/2016, and considered an active patient were eli-
gible for inclusion [17]. The final dataset included a total
of 1,544,303 individuals, who had encounters with general
practice (including clinical and administrative face-to-face
contacts and phone calls), and 7,411,945 different regis-
tered medical diagnoses during that period.
The available information from that three-year period
was used to determine the percentage of individuals with
(what we call) a “current” consultation for MSK, the per-
centage with a “current” consultation for chronic pain, and
the average number of health contacts per year. However,
to obtain more accurate data regarding (what we call) the
“prevalence” of the investigated MSK (i.e. diagnosis of arth-
ritis, chronic back pain, gout, osteoporosis, spondyloarthro-
pathies, and/or rheumatoid arthritis) [20–23], all data
available in MedicineInsight (including current data and
past electronic health records going back to 2000 for most
enrolled practices) was used to identify individuals with a
history (i.e. “prevalence”) of MSK.
Therefore, based in all available data, two different groups
of binary variables were created for the investigated MSK:
1) general “prevalence”, considering the diagnosis at any
point since 2000 (i.e. past and current health records), and;
2) “current” diagnosis/encounter for the same disease oc-
curring between 2013 and 2016 (i.e. current health records).
Patients with some of the investigated MSK were identified
from MedicineInsight databases (for both “prevalence” and
“current” diagnosis/encounter) using an algorithm that in-
cluded all diagnosis or reason for encounter (and their syn-
onyms) related to arthritis (“osteoarthritis”, “arthritis”
“polyarthritis”, “arthropathy”, “polyarthralgia”, “arthralgia”,
“osteoarthrosis”, “arthrosis”), spondyloarthropathies (“spon-
dyloarthritis”, “spondyloarthropathy”, “spondylolisthesis”,
“spondylolysis”), rheumatoid arthritis (including polymyal-
gia rheumatica), osteoporosis, gout, and/or “chronic back
pain”. Whenever a field specified the condition as uncon-
firmed (i.e. “suspected”, “under investigation”, “???”), acute
(i.e. “suppurative”, “bacterial”, “infectious”, etc.), or was just
as a “family history” (or only a relative affected by these
conditions), patients were considered as negative for that
condition.
For “current” chronic pain consultations, only one binary
variable (no/yes) was generated for data analysis, consider-
ing all consultations/diagnosis that occurred between 2013
and 2016. In that case, the terms used included “chronic
pain”, “pain treatment” and synonyms of these terms (e.g.
“chronic -algia” and “chronic -ache”). Therefore, consider-
ing these terms, “chronic back pain” was included under
“chronic pain”, but also as a MSK, as this is consistent with
clinical practice in Australia and with reports from the
Australian Institute of Health and Welfare [6, 7, 26]. Pa-
tients were considered negatives for chronic pain whenever
the condition was specified as recent/acute.
The total number of contacts with the general practice
between 2013 and 2016 (independent of whether it was or
not related to some of the investigated MSK or chronic
pain) was also extracted from the database, as well as the
date of the first and last consultation (past and “current”
health records).
“Current” patient related information was obtained from
the same database, including sex (male/ female), age (ob-
tained as groups of 5-year categories), state of residence,
rurality (major cities, inner regional, outer regional, or re-
mote Australia), Australian Socio-Economic Indexes for
Areas (SEIFA) Index of Relative Socio-economic Advantage
and Disadvantage (IRSAD) deciles, pension (none, pen-
sioner or health care card owner, Department of Veterans
Affair (DVA)), ethnicity (Aboriginal and Torres Strait
Islander yes/no), and smoking status (non-smoker, ex-
smoker, current smoker). SEIFA-IRSAD is an indicator of
relative economic and social advantage/disadvantage of
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people and households within an area [27]. The deciles
were regrouped into quintiles (higher quintile indicating the
respondent resides in a more advantaged area) for analysis.
Finally, the prevalence of some common NCDs and
their risk factors were obtained following the same pro-
cedures used to identify the “prevalence” of the investi-
gated MSK, considering medical registers since 2000
when available (past and current health records). These
conditions included cardiometabolic risk factors (hyper-
tension, diabetes mellitus, chronic kidney disease), car-
diovascular diseases (ischaemic heart disease, stroke,
heart failure), respiratory diseases (asthma, chronic ob-
structive pulmonary disease (COPD)), and mental health
conditions (depression, anxiety).
Statistical analysis
Categorical variables were expressed as proportions (%),
while median with interquartile range (p25-p75) were used
to calculate the average number of health contacts, because
of this variable’s asymmetry. Confidence intervals of 95%
(95%CI) were also estimated. The association between
sociodemographic conditions and smoking status with the
“prevalence” of the investigated MSK and chronic pain was
expressed as prevalence and prevalence ratios (PR and their
respective 95%CI estimated using Poisson regression). All
associations with the investigated MSK diseases and
“current” consultations for chronic pain were adjusted for
sex and age, and p-values of heterogeneity were used to in-
dicate those associations where the prevalence of the out-
come was different across categories of the investigated
sociodemographic variables and smoking status.
All analyses were performed in STATA 14.0 (StataCorp,
Texas, USA), considering the clusters (general practices)
and weighted to the inverse of the individual’s probability of
being in the sample (inverse of the average annual number
of contacts with the general practice = 1/average number of
contacts per year) [11, 12, 28].
The Human Research Ethics Committee of the University
of Adelaide exempted this study of an ethical review, as it
used existing and non-identifiable data.
Results
Of the total 1,544,303 active patients available in the
MedicineInsight database, 2.8% (n = 43,046) were excluded
because there was no recorded diagnosis or reason for en-
counter for the specified period (10/2013 to 06/2016). The
percentage of individuals with missing data was up to 4%
across categories of the investigated sociodemographic var-
iables, although a higher frequency was observed in the
NT (10.7%).
The final sample included for analysis consisted of
1,501,267 adults (57.6% females; 28.3% aged <35y and
22.5% ≥65y), and 65.2% of them had available records in
the MedicineInsight database prior to 2013.
The combined “prevalence” of the investigated MSK
(positive for arthritis, chronic back pain, gout, osteoporosis,
spondyloarthropathies, and/or rheumatoid arthritis, consid-
ering past and “current” health records) in the whole sam-
ple was 16.8% (95%CI 15.9;17.7) with 21.3% (95%CI
20.2;22.4) of all patients consulting for chronic pain in the
period between 2013 and 2016. Considering both variables
together, 9.4% of the sample had some of the investigated
MSK and also consulted for chronic pain (Additional file 1:
Figure S1). For instance, chronic back pain could be both a
MSK and a consultation for chronic pain.
Arthritis was the most “prevalent” of the investigated
MSK (9.5%), followed by chronic back pain (6.7%), with
3.7% of the whole sample being affected by two or more
MSK (Table 1). Among those with any of the investigated
MSK, 67.0% consulted for the same reason in the period
between 2013 and 2016, and this frequency was greater
(86.1%) among those affected by three or more MSK.
“Current” consultations for the same MSK were more fre-
quent among those affected by chronic back pain (89.3%)
or rheumatoid arthritis (57.7%). Table 1 also shows that
56.1% of the patients with any of the investigated MSK
consulted for chronic pain in the period between 2013
and 2016, and this frequency was 46% higher among those
affected by three or more MSK. A “current” consultation
for chronic pain was also more likely among those affected
by chronic back pain (96.7%), and less frequent among pa-
tients with gout (30.9%). The average number of health
contacts per year was twice as high among those with any
of the investigated MSK compared to those without these
conditions, and this number increased progressively with
the number of MSK’s in the same individual.
Figure 1 shows that the “prevalence” of the investi-
gated MSK and “current” consultations for chronic pain
increased with age, but the last remained relatively stable
for those aged 40 years or over, especially among males
(Fig. 1). The “prevalence” of chronic MSK and “current”
consultations for chronic pain were higher in males aged
20–39 years than in women of the same age, becoming
both more frequent in women than in men after the age
60 years.
The distribution of arthritis and chronic back pain ac-
cording to age and sex (Fig. 2) reflects the differences pre-
viously described for the “prevalence” of MSK and
“current” consultations for chronic pain. The “prevalence”
of chronic back pain was 20–53% more common in males
aged 20–49 years than their female peers, while no sex dif-
ferences were found for arthritis in this age. On the other
hand, the “prevalence” of arthritis increased after the age
50 years, especially among women, who were up to 29%
more likely to have this condition than men. Moreover,
although the “prevalence” of chronic back pain remained
relatively stable at around 9% in older adults, it was 25–
33% more frequent in females.
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Table 2 presents the distribution of the overall
prevalence of MSK and current consultations for
chronic pain according to sociodemographic charac-
teristics and smoking status. The overall “prevalence”
of MSK ranged from 14.7% to 19.4% across states, ex-
cept in NT where 10.2% had some of the investigated
MSK. “Current” consultations for chronic pain oscil-
lated around 20% in most states, but a higher fre-
quency was observed in the ACT and the lowest in
NT (26.1% and 8.8%, respectively). Consequently,
“current” consultations for chronic pain among pa-
tients with some of the investigated MSK were more
common in ACT (63.8%) and less frequent in NT
(38.0%). Differences in the overall “prevalence” of
MSK and “current” consultations for chronic pain
were less evident for rurality or socioeconomic pos-
ition (lower frequencies in remote Australia and in
the highest SEIFA-IRSAD quintile), and a lower pro-
portion of patients with some of the investigated
MSK consulted for chronic pain in remote Australia.
After adjustment for age and sex, the overall “preva-
lence” of MSK, “current” consultations for chronic
pain, and proportion of patients with some of the in-
vestigated MSK consulting for chronic pain were
higher in DVAs holders. Both, the overall “prevalence”
of MSK and “current” consultations for chronic pain
were more frequent in Aboriginal and Torres Strait
Islander people. However, the proportion of consulta-
tions for chronic pain among those affected by some
of the investigated MSK was similar in Aboriginals
and non-Aboriginals. The overall “prevalence” of MSK
and “current” consultations for chronic pain were
similar in ex-smokers and current smokers, while
among non-smokers these frequencies were lower.
Fig. 3 shows the overall “prevalence” of the investi-
gated MSK and chronic pain among individuals af-
fected by other chronic diseases. The investigated
MSK were more frequent among those affected by
heart failure or COPD, and less frequent among
people with diabetes mellitus. On the other hand,
“current” consultations for chronic pain among indi-
viduals with a chronic disease ranged from 25% to
29% for most diseases, with the highest values ob-
served among those affected by ischaemic heart dis-
ease, heart failure, COPD, or anxiety.
Discussion
Four principal findings can be highlighted in this study.
Firstly, the investigated MSK and consultations for
chronic pain are common, and often related, reasons for
Table 1 Prevalence of the investigated musculoskeletal diseases and characteristic related to the management of these conditions.






















No 83.2 (82.3;84.1) 0.0 14.3 1.0 [1.0–2.0] 3.3 [0.7–8.6]
Yes 16.8 (15.9;17.7) 66.7 56.1 2.0 [1.0–5.5] 6.0 [1.8–12.6]
Number of musculoskeletal
diseasesd
1 13.1 (12.5;13.7) 67.0 54.9 2.0 [1.0–4.5] 5.5 [1.6–12.1]
2 3.1 (2.8;3.4) 62.5 54.8 3.0 [1.0–8.0] 7.3 [2.5–13.9]
3+ 0.6 (0.5;0.7) 86.1 80.0 6.5 [2.0–12.5] 8.1 [3.0–14.7]
Type of musculoskeletal
disease
Arthritis 9.5 (8.8;10.3) 48.3 40.0 2.5 [1.0–6.5] 7.7 [2.9–14.0]
Chronic back pain 6.7 (6.4;7.1) 89.3 96.7 2.0 [1.0–5.0] 4.5 [1.3–10.3]
Gout 1.6 (1.5;1.7) –e 30.9 1.5 [1.0–4.0] 4.2 [1.1–10.4]
Osteoporosis 1.2 (1.1;1.4) –e 38.5 3.5 [1.0–9.0] 5.7 [1.3–13.1]
Spondyloarthropathies 1.1 (0.9;1.3) 8.4 46.5 3.0 [1.0–7.5] 9.2 [3.9–14.8]
Rheumatoid arthritis 0.9 (0.8;1.0) 57.7 35.0 2.5 [1.0–7.5] 7.2 [2.1–14.1]
a Considering the whole period since the first register available in the MedicineInsight dataset (2000–2016)
b Consultations between Oct/2013 and June/2016
c Number of registers on different dates when the patient received some diagnosis and/or some encounter occurred between the patient and the health service,
including face-to-face visits and telephone contacts
d Positives for arthritis, chronic back pain, gout, osteoporosis, spondyloarthropathies, and/or rheumatoid arthritis
e No data available on diagnosis for these conditions before 2013
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presentation in Australian general practice. Secondly, pa-
tients affected by some of the investigated MSK attend
general practice more frequently than those without these
conditions. Thirdly, although the overall “prevalence” of
the investigated MSK increases with age, the rate of
“current” consultation for chronic pain remains stable
once patients reach 40–49 years of age, especially among
males. Finally, there appears to be some geographical and
socioeconomic differences in the overall “prevalence” of
the investigated MSK and “current” consultations for
chronic pain in Australia that need to be explained.
Previous estimates for the prevalence of MSK are simi-
lar to our “prevalence” obtained from MedicineInsight
data [29], although we might expect a higher frequency
in our study compared to community based surveys, be-
cause our participants are attending a doctor, which
makes them less likely to be healthy than general popu-
lation [17]. Using self-report data, the AIHW estimated
that osteoarthritis affects 8.0% of all Australians adults,
back pain 7.1%, osteoporosis 3.1%, and rheumatoid arth-
ritis 1.9%. However, the use of self-reported information
can undermine the ability to truly identify the scale of
MSK within the population, especially for chronic pain,
as the reliability of this information is also affected by
question wording [15]. According to the BEACH pro-
gram, chronic pain among Australian patients attending
general practices changed from 18% in 2005 (N = 3211)
to 19% in 2008–09 (N = 5793) [11, 26]. Therefore, the
results obtained from MedicineInsight are similar to
these previous estimates, with the advantage of provid-
ing results from a very large sample, which can be con-
sidered nationally representative of Australian adults
(demographic distribution comparable to the census)
[17, 30]. It is also based on medical diagnosis rather than
self-report. Different countries have demonstrated that
data from primary health care electronic records are ac-
curate for the investigation of different diseases and their
risk factors (sensitivity, specificity, and predictive posi-
tive values ranging from 70 to 95%) [19–23]. Programs
like MedicineInsight are an excellent opportunity for
governments to ascertain clinical outcomes on a large
scale, at low cost, and with the potential to link to other
data sources, thus facilitating monitoring and planning
by heath policy makers [31]. Our findings also highlight
the importance of these conditions in Australian health
care because of their chronicity, rising health care costs,
higher frequency among individuals affected by other
chronic conditions, and adverse effects on patients’ qual-
ity of life [6, 7, 32, 33].
It has been shown previously that MSK are a common
reason for consultation in general practice, increasing
with age and being more frequent in females [10, 34].
Chronic pain has also been reported to be more frequent
among the less educated, those with lower family in-
come, the physically inactive, smokers, and among those
with depression [29], which is consistent with our re-
sults. Additionally, some studies have also found a
higher frequency of chronic pain among women and a
progressive increase with age, with a reduction after the
age of 65 years, which is also consistent with our find-
ings [11, 29, 35]. The reduction in the “prevalence” of
chronic pain in the elderly may be a consequence of
fewer work place related physical adverse effects post
retirement [29, 35]. However, this could be also second-
ary to GPs recording MSK more frequently than chronic
Fig. 2 Prevalence of chronic back pain and arthritis by age and sex.
“Prevalence” estimations considering the whole period since the first
register available in the MedicineInsight dataset (2000–2016). Results
for adults (18+ years) who attended one of the 329 Australian General
Practices participating in the MedicineInsight program (N = 1,501,267).
Vertical lines represent 95%CIs
Fig. 1 Overall prevalence of the investigated MSK and current
consultation for chronic pain by age and sex. For “prevalence”, the
whole period since the first register available in the MedicineInsight
dataset (2000–2016) was considered, while “current consultation”
considers the period between Oct/2013 and June/2016. Results for
adults (18+ years) who attended one of the 329 Australian General
Practices participating in the MedicineInsight program (N = 1,501,267).
Vertical lines represent 95%CIs
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Table 2 Prevalence of the investigated musculoskeletal diseases and consultations for chronic pain according to sociodemographic
characteristics and smoking status. Adults aged 18+ years (N = 1,501,267)






% of patients with a
MSK that consulted for
chronic pain (2013–2016)b
%%c PR (95%CI)c %c PR (95%CI)c
State P < 0.001 P = 0.006
New South Wales (NSW) 28.2 17.6 Ref 22.7 Ref 57.5
Victoria (VIC) 25.5 16.5 0.94 (0.85–1.04) 22.2 0.98 (0.84–1.14) 58.1
Queensland (QLD) 18.7 16.9 0.96 (0.88;1.06) 19.8 0.87 (0.77–0.99) 53.4
Western Australia (WA) 13.3 14.7 0.83 (0.72–0.96) 19.1 0.84 (0.72–0.99) 55.9
Tasmania (TAS) 8.0 19.4 1.10 (1.01–1.21) 21.8 0.96 (0.83–1.12) 52.8
South Australia (SA) 3.4 17.3 0.98 (0.87;1.11) 22.3 0.98 (0.82–1.17) 54.9
Australia Capital Territory (ACT) 1.6 18.8 1.07 (0.73;1.58) 26.1 1.15 (0.77–1.71) 63.8
North Territory (NT) 1.3 10.2 0.58 (0.39;0.88) 8.8 0.39 (0.22–0.67) 38.0
Rurality P = 0.05 P = 0.07
Major cities 63.0 16.4 Ref 21.4 Ref 57.2
Inner regional 24.2 18.1 1.11 (1.02–1.20) 22.4 1.05 (0.93–1.17) 55.5
Outer regional 11.2 16.9 1.03 (0.95–1.12) 19.4 0.91 (0.80–1.02) 52.4
Remote Australia 1.6 14.6 0.89 (0.71–1.12) 16.6 0.78 (0.61–1.00) 49.0
Socioeconomic position
(SEIFA-IRSAD quintiles)
P < 0.001 P < 0.001
1 (Lowest) 17.3 18.9 Ref 23.8 Ref 57.1
2 15.7 19.1 1.01 (0.93–1.08) 23.5 0.99 (0.90–1.08) 57.2
3 20.5 16.5 0.87 (0.80–0.94) 20.2 0.85 (0.77–0.93) 54.2
4 20.1 16.5 0.87 (0.81–0.94) 21.2 0.89 (0.81–0.98) 56.3
5 (Highest) 26.4 14.6 0.77 (0.71–0.84) 19.6 0.83 (0.74–0.93) 56.0
Pension P < 0.001 P < 0.001
None 22.9 13.3 Ref 17.8 Ref 51.5
Pensioner or health care card 32.6 21.7 1.64 (1.52–1.76) 26.0 1.46 (1.32–1.63) 59.0
Department of Veterans Affair 1.3 24.1 1.82 (1.68–1.98) 29.6 1.66 (1.47–1.88) 60.8
Ignored 43.2 14.3 1.08 (0.98–1.19) 20.3 1.14 (1.00–1.31) 55.1
Aboriginal or Torres Strait Islander P < 0.001 P < 0.001
No 69.7 17.6 Ref 22.2 Ref 56.9
Yes 1.8 22.9 1.30 (1.22–1.39) 25.8 1.16 (1.08–1.24) 58.2
Ignored 28.6 14.7 0.83 (0.79–0.88) 19.0 0.85 (0.80–0.91) 53.8
Smoking status P < 0.001 P < 0.001
Non-smoker 50.3 16.8 Ref 21.3 Ref 54.8
Ex-smoker 20.1 19.8 1.17 (1.15–1.19) 24.4 1.14 (1.12–1.17) 57.2
Current smoker 14.5 20.5 1.22 (1.19–1.25) 24.8 1.17 (1.12–1.21) 59.4
Ignored 15.1 10.0 0.65 (0.61–0.70) 15.7 0.69 (0.64–0.75) 54.4
a Considering the whole period since the first register available in the MedicineInsight dataset (2000–2016), and including those positives for arthritis, chronic
back pain, gout, osteoporosis, spondyloarthropathies and/or rheumatoid arthritis
b Consultation between 10/2013 and 06/2016
c Prevalence, prevalence ratios (PR) and p-values estimated based on Poisson Regression models, adjusted for sex and age. P-values of heterogeneity indicating
differences across categories of each independent variable
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pain as the reason for encounter once they confirm the
diagnosis, or given the increase in comorbidity with age,
the reporting of chronic pain may slip down the list of
priorities compared to the other conditions older people
have. However, some biological explanations are also
possible. For instance, MSK developed later in life may
be less painful due to a higher pain threshold associated
with a loss of primary afferent fibres, reduction of pain
receptors, or pain indifference resulting from a history
of other chronic problems [36, 37].
More difficult to explain are the differences in consult-
ation rates for chronic pain related to MSK between
States, which has not been reported before in Australia
[6, 11, 12, 32, 34], and may relate to differential access
to general practice (i.e. poor access in non-urban loca-
tions) or recording of the reason for consultation, such
as in the NT, where the percentage of excluded individ-
uals due to missing data was 10.7%.
An advantage of using routinely collected morbidity
data is the ability to examine the relationship between
conditions. As expected, those with anxiety were more
likely to consult for chronic pain [38]. Amongst co-
morbidities, the overall prevalence of the investigated
MSK and chronic pain were particularly high among
those affected by heart failure and COPD. This relation-
ship has been reported previously [39–42] and attributed
to abnormal inflammatory responses in extra-articular
tissues, co-morbid depression and anxiety, insomnia,
related symptoms (i.e. cough making pain worse,
oedema), musculoskeletal fatigue, and restricted use
of non-steroidal anti-inflammatory drugs for pain
management.
In the absence of a disease register for MSK in general
practice, MedicineInsight provides an alternative to popu-
lation surveys. However, there are some limitations that
should be highlighted. Firstly, not everyone with a MSK
needs to see a GP regularly for diagnosis or management.
For instance, most people over the age of 65 will have
osteoarthritis or some other MSK, but not everyone will
require regular medical care for these conditions [6, 7].
Secondly, depending on how critical information is re-
corded (e.g. missing data, non-mandatory fields, free-text
for coding, different system coding vocabularies) or ex-
tracted (algorithms for data extraction), the accuracy of
the information may be compromised [20–23, 43]. Al-
though 2.8% of the individuals were excluded due to miss-
ing data on diagnosis or reason for encounter, it is very
unlikely that it could have biased the results, as they were
similar to the investigated sample according to sex, age,
rurality, socioeconomic position, aboriginality or smoking
status. Even though diverse methods were used to im-
prove data quality (i.e. general practice characteristics,
fields used for data extraction, variability of terms and syn-
onyms), the algorithms used by MedicineInsight for data
extraction have not been validated [28]. Furthermore, con-
sidering the non-random sampling process used for the
enrolment of general practices and restrictions defined by
MedicineInsight to get them included in the datasets,
smaller practices are more likely to be underrepresented.
However, the investigated sample seems to be representa-
tive of the Australian population, as the distribution in
terms of gender, age, socioeconomic position, state, and
rurality closely resembles figures from the last census [17,
30]. In any case, considering all these issues, Medicine-
Wise is continuously expanding the number of recruited
general practices and working towards the standardisation
of its own data coding and extraction procedures [17].
Thirdly, diseases that are longstanding may only be
recorded at initial diagnosis and a snapshot of GP attend-
ance may not pick up the sentinel event. Including a lon-
ger period of data collection for the same patients and
using a list of synonyms for the investigated conditions
could improve the sensitivity to identify MSK cases and
overcome these limitations.
Conclusions
The investigated MSK were an important and frequent
reason for consultation in Australian general practice, espe-
cially among lower socioeconomic groups and the elderly.
The distribution of these conditions differed according to
other demographic characteristics and presence of comor-
bidities. Based on information collected from adults attend-
ing Australian general practices, MedicineInsight provided
similar estimates to those obtained from population-based
Fig. 3 Overall prevalence of the investigated musculoskeletal diseases
and current consultation for chronic pain according to the presence of
chronic diseases. For “prevalence”, the whole period since the first
register available in the MedicineInsight dataset (2000–2016) was
considered, while “current consultation” considers the period between
Oct/2013 and June/2016. Results for adults (18+ years) who attended
one of the 329 Australian General Practices participating in the
MedicineInsight program (N= 1,501,267). Values in parenthesis are the
prevalence of each chronic disease. Vertical lines represent 95%CIs.
Results are age and sex adjusted
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studies, with the advantage of being based on medical
diagnosis and including a national sample.
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of the investigated musculoskeletal diseases and current consultation for
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available in the MedicineInsight dataset (2000-2016) was considered,
while “current consultation” considers the period between Oct/2013 and
June/2016. Results for adults (18+ years) who attended one of the 329
Australian General Practices participating in the MedicineInsight program
(N=1,501,267). (DOC 218 kb)
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